Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of T cell differentiation in the thymus. [GOC:add, GOC:mah]
Positive regulation of T cell differentiation in the thymus is a complex and tightly regulated process that involves a series of checkpoints and interactions between developing thymocytes and thymic stromal cells. The thymus is a primary lymphoid organ where T cells undergo development and maturation. The process starts with hematopoietic stem cells migrating to the thymus, where they differentiate into double-negative (DN) thymocytes, lacking both CD4 and CD8 coreceptors. These DN thymocytes undergo a series of stages (DN1-DN4) characterized by the expression of specific transcription factors and surface markers. During the DN stage, thymocytes undergo beta-selection, ensuring successful rearrangement of the beta chain of the T cell receptor (TCR). Upon successful beta-selection, thymocytes differentiate into double-positive (DP) cells, expressing both CD4 and CD8.
The DP stage is crucial for the selection of thymocytes based on their TCR affinity for self-antigens presented by thymic epithelial cells. This process, known as positive selection, ensures that only T cells recognizing self-antigens with an appropriate affinity survive and mature. Thymocytes that fail to interact with self-antigens undergo apoptosis, a process called negative selection. Positive selection occurs in the thymic cortex, where DP thymocytes interact with self-antigens presented by cortical epithelial cells. The interaction between the TCR and self-antigen triggers signaling cascades that lead to the upregulation of survival factors and the downregulation of pro-apoptotic proteins, promoting the survival and differentiation of the thymocyte. This interaction also leads to the commitment of DP thymocytes to either the CD4+ or CD8+ lineage.
The fate of a DP thymocyte is determined by the strength of the TCR-mediated signaling. Strong interactions with self-antigens lead to CD8+ lineage commitment, while weaker interactions favor the CD4+ lineage. This lineage commitment is accompanied by changes in the expression of specific transcription factors, including Runx3 for CD8+ and Th-POK for CD4+.
Following positive selection, thymocytes migrate to the thymic medulla, where they undergo negative selection. In this stage, thymocytes encounter a wider range of self-antigens presented by various stromal cells, including medullary epithelial cells, dendritic cells, and macrophages. If thymocytes interact too strongly with self-antigens, they are eliminated by apoptosis. This process ensures that only T cells with a low affinity for self-antigens mature and exit the thymus, preventing autoimmune reactions.
The positive regulation of T cell differentiation in the thymus is mediated by various factors, including:
* **Cytokines**: IL-7, IL-15, and TGF-beta play crucial roles in supporting the survival, proliferation, and differentiation of thymocytes at different stages.
* **Transcription factors**: Transcription factors such as Notch1, GATA-3, Runx3, and FoxP3 regulate the expression of genes involved in thymocyte development and lineage commitment.
* **Receptor signaling**: The TCR complex, along with other receptors like CD28 and CD45, mediate signaling events that guide thymocyte selection and differentiation.
* **Thymic stromal cells**: Thymic epithelial cells, dendritic cells, and macrophages provide essential signals and interactions for thymocyte development and selection.
Overall, the positive regulation of T cell differentiation in the thymus is a tightly controlled process involving a series of checkpoints and interactions that ensure the generation of a diverse repertoire of mature T cells capable of recognizing foreign antigens while avoiding self-reactivity. This intricate process is critical for the establishment and maintenance of an efficient and self-tolerant immune system.'
"
Protein | Definition | Taxonomy |
---|---|---|
Sonic hedgehog protein | A sonic hedgehog protein that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15465] | Homo sapiens (human) |
Disintegrin and metalloproteinase domain-containing protein 8 | A disintegrin and metalloproteinase domain-containing protein 8 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P78325] | Homo sapiens (human) |
Zinc finger protein GLI2 | A zinc finger protein GLI2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P10070] | Homo sapiens (human) |
Adenosine deaminase | An adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
9-(2-hydroxy-3-nonyl)adenine | 9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase | ||
staurosporine aglycone | staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor | ||
jervine | jervine: teratogen from Veratrum grandiflorum; RN given refers to parent cpd(3beta,23beta)-isomer; structure | piperidines | |
coformycin | coformycins | EC 3.5.4.4 (adenosine deaminase) inhibitor | |
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
nebularine | nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage. nebularine: structure | purine ribonucleoside; purines D-ribonucleoside | fungal metabolite |
9-(2-hydroxy-3-nonyl)adenine | (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | EHNA | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor |
9-(2-hydroxy-3-nonyl)adenine | (2S,3R)-EHNA : EHNA of absolute configuration 2S,3R. | EHNA | |
1-deazaadenosine | 1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source | ||
pentostatin | pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | coformycins | antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor |
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
zerumbone | zerumbone : A sesquiterpenoid and cyclic ketone that is (1E,4E,8E)-alpha-humulene which is substituted by an oxo group at the carbon atom attached to two double bonds. It is obtained by steam distillation from a type of edible ginger, Zingiber zerumbet Smith, grown particularly in southeast Asia. zerumbone: RN given for (E,E,E)-isomer; structure in first source | cyclic ketone; sesquiterpenoid | anti-inflammatory agent; glioma-associated oncogene inhibitor; plant metabolite |
8-azanebularine | 8-azanebularine: structure in first source | ||
cur 61414 | CUR 61414: inhibits the hedehog signaling pathway; structure in first source | ||
incb3619 | INCB3619: ADAM inhibitor; structure in first source | ||
msh, 4-nle-7-phe-alpha- | polypeptide | dermatologic drug | |
gdc 0449 | HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity | benzamides; monochlorobenzenes; pyridines; sulfone | antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent |
robotnikinin | robotnikinin: binds sonic hedgehog protein to block its signaling pathway; structure in first source |